Equities

TherapeuticsMD Inc

TherapeuticsMD Inc

Actions
  • Price (USD)2.11
  • Today's Change-0.03 / -1.40%
  • Shares traded18.53k
  • 1 Year change-53.01%
  • Beta1.0196
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

  • Revenue in USD (TTM)1.20m
  • Net income in USD-6.20m
  • Incorporated2010
  • Employees1.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zivo Bioscience Inc63.37k-7.08m22.60m8.00------356.62-3.83-3.830.0318-0.81330.0652----7,921.25-728.52-376.60----38.05---11,176.47-96,315.32---88.46--------11.07------
Eom Pharmaceutical Holdings Inc0.00-4.93m22.65m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
Nymox Pharmaceutical Corp0.00-4.87m22.93m3.00---------0.0536-0.05360.00-0.02040.00-------255.75-264.40---464.48-------13,001.67---42.44--------47.55------
Bullfrog AI Holdings, Inc.65.00k-5.95m23.00m4.00--3.38--353.88-0.8903-0.89030.00970.86670.0094----16,250.00-85.49---103.85--92.00---9,129.42-----278.200.0694--550.00---91.11------
Iterum Therapeutics PLC0.00-35.58m23.01m14.00---------2.64-2.640.00-0.37340.00----0.00-91.54-118.12-136.45-199.23-------890,554.10----1.44------13.64---32.09--
Bioxytran Inc0.00-4.30m23.27m2.00---------0.0297-0.02970.00-0.00170.00-------2,431.80-1,420.53---------------7.69---------73.71------
Qilian International Holding Group Ltd46.47m-7.78m23.59m298.00--0.5513--0.5077-0.2176-0.21761.301.200.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
Apollomics Inc0.00-388.09m23.72m----0.4257-----4.34-4.340.000.6225---------------------------1,391.690.012-------154.03------
SAB Biotherapeutics Inc2.24m-42.19m23.89m57.00--0.417--10.67-7.18-7.180.40566.210.0332--0.805939,280.53-62.58---77.39-------1,884.50------0.0743---90.63---125.14------
Biomx Inc0.00-26.17m24.07m58.00--5.15-----0.5433-0.54330.000.0670.00----0.00-74.18---101.74-------------21.950.7841------7.59------
TherapeuticsMD Inc1.20m-6.20m24.33m1.00--0.8489--20.29-0.58-0.69550.11032.490.0236--0.45561,199,000.00-12.19-53.35-16.34-111.6173.8986.67-516.93-236.57----0.00---98.14-39.53-816.85------
Unity Biotechnology Inc0.00-34.78m24.51m19.00--1.02-----2.33-2.330.001.430.00----0.00-40.18-47.21-48.47-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Acasti Pharma Inc0.00-38.77m24.91m32.00--0.3851-----5.06-5.060.006.880.00-------40.18-45.71-41.30-50.84-------69,798.47---14.380.00-------332.11---45.53--
Jaguar Health Inc10.14m-38.32m25.08m49.00--1.95--2.47-78.63-78.639.903.180.18060.23978.12206,938.80-69.22-95.29-122.86-163.5479.0767.28-383.35-522.281.39-2.780.6919---18.3617.1912.97------
Data as of May 23 2024. Currency figures normalised to TherapeuticsMD Inc's reporting currency: US Dollar USD

Institutional shareholders

27.78%Per cent of shares held by top holders
HolderShares% Held
Rubric Capital Management LPas of 31 Mar 20241.19m10.34%
Clearline Capital LPas of 31 Mar 2024535.34k4.64%
Tejara Capital Ltd.as of 31 Mar 2024401.94k3.49%
The Vanguard Group, Inc.as of 31 Mar 2024382.65k3.32%
Adar1 Capital Management LLCas of 31 Mar 2024272.16k2.36%
BlackRock Fund Advisorsas of 31 Mar 2024134.51k1.17%
Morgan Stanley & Co. LLCas of 31 Mar 2024130.50k1.13%
Geode Capital Management LLCas of 31 Mar 202484.79k0.74%
Bridgeway Capital Management LLCas of 31 Mar 202439.10k0.34%
SSgA Funds Management, Inc.as of 31 Mar 202430.10k0.26%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.